	US 12,247,973 B2
	Plasma membrane citrate transporter for use in the diagnosis and treatment of cancer
Edward Geissler, Regensburg (DE); Maria Mycielska, Regensburg (DE); and Petra Rümmele, Regensburg (DE)
Assigned to Universitätsklinikum Regensburg, Regensburg (DE)
Filed by Universitätsklinikum Regensburg, Regensburg (DE)
Filed on Aug. 26, 2020, as Appl. No. 17/003,750.
Application 17/003,750 is a division of application No. 15/514,255, granted, now 10,768,167, previously published as PCT/EP2015/072098, filed on Sep. 25, 2015.
Claims priority of application No. 14186315 (EP), filed on Sep. 25, 2014.
Prior Publication US 2020/0408741 A1, Dec. 31, 2020
Int. Cl. G01N 33/50 (2006.01); A61K 39/00 (2006.01); C07K 16/18 (2006.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01)

CPC G01N 33/5011 (2013.01) [C07K 16/18 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01); C12Q 2600/158 (2013.01); G01N 2500/04 (2013.01); G01N 2500/10 (2013.01); G01N 2800/56 (2013.01)]

5 Claims

1. A method of treating pancreatic cancer or prostate cancer in a patient in need thereof, the method comprising:

a) providing a tissue or blood sample from the patient;

b) determining the presence and/or amount of plasma membrane citrate transporter (pmCiC) in said sample, wherein the presence and/or amount of said pmCiC is indicative for existence and/or aggressiveness of pancreatic cancer or prostate cancer in said tissue or blood sample; and

c) treating the pancreatic cancer or the prostate cancer, wherein treating the pancreatic cancer or the prostate cancer comprises administering to the patient an inhibitor of pmCiC activity, wherein the inhibitor of pmCiC activity is selected from gluconate and siRNA.